The efficacy of rituximab in the treatment of inhibitor-associated hemostatic disorders

Summary

Rituximab is a chimeric anti-CD20 monoclonal antibody active against normal and malignant B cells which has proven to be effective in the therapy of CD-20 positive lymphomas. Its B-cell cytotoxic action has also been exploited in many non-malignant autoimmune disorders in which it has been used with the aim of interfering with the production of pathologic antibodies. The present knowledge regarding the use of rituximab in antibodyassociated disorders of hemostasis (i.e. idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura, acquired hemophilia A, congenital hemophilia with inhibitors, acquired inhibitors against coagulation factors) is presented briefly in this review. The results suggest that rituximab can be useful in the treatment of disorders of hemostasis associated with inhibitor formation. Although collectively the number of patients treated is now quite substantial, most of the data are drawn from isolated case reports or descriptions of small, uncontrolled series. Large, prospective, randomized trials are, therefore, needed to confirm the positive, preliminary results.

Keywords

Rituximab - inhibitor - coagulation disorders

• References

• 1 Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 2003; 14: 520-5.
• 2 Yomtovian R, Niklinski W, Silver B. et al. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. Br J Haematol 2004; 124: 787-95.
• 3 Leandro MJ, Edwards JC, Cambridge G. et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthr Rheum 2002; 46: 2673-7.
• 4 Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 2002; 61: 883-8.
• 5 Hongeng S, Tardtong P, Worapongpaiboon S. et al. Successful treatment of refractory autoimmune haemolytic anaemia in a post-unrelated bone marrow transplant paediatric patient with rituximab. Bone Marrow Transplant 2002; 29: 871-2.
• 6 Zaja F, Iacona I, Masolini P. et al. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica 2003; 87: 189-95.
• 7 Zecca M, Nobili B, Ramenghi U. et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 2003; 101: 3857-61.
• 8 Berentsen S, Tjonnfjord GE, Brudevold R. et al. Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease. Br J Haematol 2001; 115: 79-83.
• 9 Zaja F, De Vita S, Mazzaro C. et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003; 101: 3827-34.
• 10 Franchini M, Gandini G, Di Paolantonio T. et al. Acquired hemophilia A: a concise review. AmJ Hematol 2005; 80: 55-63.
• 11 Pestronk A, Florence J, Miller T. et al. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psych 2003; 74: 485-9.
• 12 Remuzzi G, Chiurchiu C, Abbate M. et al. Rituximab for idiopathic membranous nephropathy. Lancet 2002; 360: 923-4.
• 13 Zaja F, Vianelli N, Sperotto A. et al. B-cell compartment as the selective target for the treatment of immune thrombocytopenias. Haematologica 2003; 88: 538-46.
• 14 Mathias M, Khair K, Hann I. et al. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia. BrJ Haematol 2004; 125: 366-8.
• 15 Perotta A, Sunneberg TA, Scott J. et al. Rituxan in the treatment of chronic idiopathic thrombocytopenic purpura (ITP). Blood 1999; 94: 14a [abstract].
• 16 Grossi A, Santini V, Longo G. et al. Treatment with anti-CD 20 antibodies of patients with autoimmune thrombocytopenia with or without haemolytic anemia; worsening in hemoglobin level. Blood 2000; 96: 253a [abstract].
• 17 Saleh MN, Gutheil J, Moore M. et al. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin Oncol 2000; 27 (Suppl. 12) 99-103.
• 18 Faurschou M, Hasselbalch HC, Nielsen OJ. Sustained remission of platelet counts following monoclonal anti-CD20 antibody therapy in two cases of idiopathic autoimmune thrombocytopenia and neutropenia. Eur J Haematol 2001; 66: 408-11.
• 19 Stasi R, Pagano A, Stipa E. et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001; 98: 952-7.
• 20 Stasi R, Stipa E, Forte V. et al. Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. Blood 2002; 99: 3872-3.
• 21 Giagounidis AA, Anhuf J, Schneider P. et al. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: A pilot study. Eur J Haematol 2002; 69: 95-100.
• 22 Shanafelt TD, Madueme HL, Wolf RC. et al. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Mayo Clin Proc 2003; 78: 1340-6.
• 23 Bengston KL, Skinner MA, Ware RE. Successful use of anti-CD20 (rituximab) in severe, life-threatening childhood immune thrombocytopenic purpura. J Pediatr 2003; 143: 670-3.
• 24 Braendstrup P, Pedersen M, Bjerrum OW. et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with refractory idiopathic thrombocytopenic purpura. Blood 2003; 102: 1066 [abstract].
• 25 Shenoy S, Kelly M, Grossman W. et al. Rituximab therapy in children with chronic refractory immune cytopenia: long term efficacy and immune function analysis. Blood 2003; 102: 1020 [abstract].
• 26 Wiley JM, Wang J, Luddy RE. et al. Efficacy and safety of rituxan treatment in children with chronic immune thrombocytopenic purpura (ITP). Blood 2003; 102: 1062 [abstract].
• 27 Ahmad HN, Ball C, Height SE. et al. Rituximab in chronic, recurrent HIV-associated immune thrombocytopenic purpura. Br J Haematol 2004; 127: 607-8.
• 28 Cooper N, Stasi R, Cunningham-Rundles S. et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 2004; 125: 232-9.
• 29 Moschovi M, Trimis G, Pergantou H. et al. Clinical remission following monoclonal anti-CD20 therapy in two children with chronic refractory idiopathic thrombocytopenic purpura. J Paediatr Child Health 2005; 41: 384-6.
• 30 Narat S, Gandla J, Hoffbrand AV. et al. Rituximab in the treatment of refractory autoimmune cytopenias in adults. Haematologica 2005; 90: 1273-4.
• 31 Taube T, Schmid H, Reinhard H. et al. Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood. Haematologica 2005; 90: 281-3.
• 32 Bennet CM, Rogers ZR, Kinnamon DD. et al. Prospective phase I/II study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 2006; 107: 2639-42.
• 33 Wang J, Wiley JM, Luddy R. et al. Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. J Pediatr 2005; 146: 217-21.
• 34 Garcia-Chavez J, Vela-Ojeda J, Gonzalez-Acosta JC. et al. Treatment of refractory chronic immune thrombocytopenic purpura (ITP) with rituximab: report of a case series. Blood 2005; 106: 4007 [abstract].
• 35 Ahn ER, Bidot C, Fontana V. et al. Rituximab therapy induces long lasting remissions and reduction of anti-platelet glycoprotein autoantibodies in patients with chronic immune thrombocytopenic purpura (ITP). Blood 2005; 106: 4006 [abstract].
• 36 Case DC, Hedlund JA, Ebrahim KS. et al. Rituximab produces long-term responses in immune thrombocytopenic purpura (ITP). Blood 2005; 106: 3977 [abstract].
• 37 Vesely SK, Perdue JJ, Rizvi MA. et al. Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy: a systematic review. Ann Intern Med 2004; 140: 112-20.
• 38 Stasi R, Provan D. Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc 2004; 79: 504-22.
• 39 Chong BH, Ho SJ. Autoimmune thrombocytopenia. J Thromb Haemost 2005; 03: 1763-72.
• 40 Bukowski RM. Thrombotic thrombocytopenic purpura: a review. Prog Hemost Thromb 1982; 06: 287-337.
• 41 Franchini M, Zaffanello M, Veneri D. Advances in the pathogenesis, diagnosis and treatment of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Thromb Res 2006; 118: 177-84.
• 42 Cataland SR, Wu HM. Immunotherapy for thrombotic thrombocytopenic purpura. Curr Opin Hematol 2005; 12: 359-63.
• 43 Gutterman L, Kloster B, Tsai HM. Rituximab therapy for refractory thrombotic thrombocytopenic purpura. Blood Cells Mol Dis 2002; 28: 385-91.
• 44 Chemnitz J, Draube A, Scheid C. et al. Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab. Am J Hematol 2002; 71: 105-8.
• 45 Zheng X, Pallera AM, Goodnough LT. et al. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Ann Intern Med 2003; 138: 105-8.
• 46 Tsai HM, Schulman K. Rituximab induces remission of cerebral ischemia caused by thrombotic thrombocytopenic purpura. Eur J Haematol 2003; 70: 183-5.
• 47 Yomtovian R, Niklinski W, Silver B. et al. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. Br J Haematol 2004; 124: 787-95.
• 48 Ahmad A, Aggarwal A, Sharma D. et al. Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP). Am J Hematol 2004; 77: 171-6.
• 49 Sallah S, Husain A, Wan JY. et al. Rituximab in patients with refractory thrombotic thrombocytopenic purpura. J Thromb Haemost 2004; 02: 834-6.
• 50 Stein GY, Zeidman A, Fradin Z. et al. Treatment of resistant thrombotic thrombocytopenic purpura with rituximab and cyclophosphamide. Int J Hematol 2004; 80: 94-6.
• 51 Fakhouri F, Teixeira L, Delarue R. et al. Responsiveness of thrombotic thrombocytopenic purpura to rituximab and cyclophosphamide. Ann Intern Med 2004; 140: 314-5.
• 52 Fakhouri F, Vernant JP, Veyradier A. et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 2005; 106: 1932-7.
• 53 Reddy PS, Deauna-Limayo D, Cook JD. et al. Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura. Ann Hematol 2005; 84: 232-5.
• 54 Millward PM, Bandarenko N, Chang PP. et al. Cardiogenic shock complicates successful treatment of refractory thrombotic thrombocytopenia purpura with rituximab. Transfusion 2005; 45: 1481-6.
• 55 Galbusera M, Bresin E, Noris M. et al. Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report. Blood 2005; 106: 925-8.
• 56 Alcaraz J, Gonzales-Garcia C, Majado MJ. et al. Rituximab in three cases of refractory thrombotic thrmbocytopenic purpura. Blood 2005; 106: 4008 [abstract].
• 57 Bortolheiro TC, Castro NS, Rodolfo CD. Rituximab for the treatment of recurrent thrombotic thrombocytopenic purpura. Blood 2006; 106: 4020 [abstract].
• 58 Giuffrida G, Figuera A, Cingari R. et al. Rituximab in chronic relapsing acquired thrombotic thrombocytopenic purpura. Blood 2005; 106: 3997 [abstract].
• 59 Scully M, Cavenagh J, Hagger D. et al. Normalisation of ADAMTS13 activity and disappearance of ADAMTS13 antibody following rituximab in acute refractory thrombotic thrombocytopenic purpura. Blood 2005; 106: 1230 [abstract].
• 60 Scott SM, Szczepiorkowski ZM. Rituximab for TTP. Am J Hematol 2005; 80: 87-8.
• 61 Koulova L, Alexandrescu D, Dutcher JP. et al. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases. Am J Hematol 2005; 78: 49-54.
• 62 Kosugi S, Matsumoto M, Ohtani Y. et al. Rituximab provided long-term remission in a patient with refractory relapsing thrombotic thrombocytopenic purpura. Int J Hematol 2005; 81: 433-6.
• 63 Gianfaldoni G, Antonioli E, Mannelli F. et al. Chronic relapsing thrombotic thrombocytopenic purpura successfully treated with rituximab: case report. J Chemother 2005; 17: 449-51.
• 64 Kessler CM. New perspectives in hemophilia treatment. Hematology (Am Soc Hematol Educ Program) 2005; 429-35.
• 65 Karwal MW, Schlueter AJ, Zenk DW. et al. Treatment of acquired factor VIII deficiency with rituximab. Blood 2000; 96: 84b [abstract].
• 66 Karwal MW, Schlueter AJ, Zenk DW. et al. Treatment of acquired factor VIII deficiency with rituximab. Blood 2000; 98: 533a [abstract].
• 67 Wiestner A, Cho HJ, Asch AS. et al. Rituximab in the treatment of acquired factor VIII inhibitors. Blood 2002; 100: 3426-8.
• 68 Kain S, Copeland TS, Leahy NF. Treatment of refractory autoimmune (acquired) haemophilia with anti-CD20 (rituximab). Br J Haematol 2002; 119: 578.
• 69 Fischer KG, Deschler B, Lubbert M. Acquired high-titer factor VIII inhibitor: fatal bleeding despite multimodal treatment including rituximab preceded by multiple plasmaphereses. Blood 2003; 101: 3753-4.
• 70 Marietta M, Pozzi S, Luppi M. et al. Acquired haemophilia in HIV negative, HHV-8 positive multicentric Castleman’s disease: a case report. Eur J Haematol 2003; 70: 181-2.
• 71 Jy W, Gagliano-DeCesare T, Kett DH. et al. Life-threatening bleeding from refractory acquired FVIII inhibitor successfully treated with rituximab. Acta Haematol 2003; 109: 206-8.
• 72 Low BG, Cohen AJ. Complete remission in hightitre acquired factor VIII inhibitor after rituximab therapy. Blood 2003; 102: 101b [abstract].
• 73 Mazj S, Li H, Lichtman SM. et al. Successful treatment of acquired factor VIII inhibitor with rituximab in four patients. Blood 2003; 102: 101b [abstract].
• 74 Stasi R, Brunetti M, Stipa E. et al. Selective Bcell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood 2004; 103: 4424-8.
• 75 Grimley C, Dolan G. Successful treatment of acquired haemophilia unresponsive to conventional immunosuppression with rituximab (anti-CD20 antibody). Haemophilia 2004; 10: 12PO34 [abstract].
• 76 Riess H. Successful treatment of refractory acquired hemophilia with the anti-CD20 antibody rituximab. Haemophilia 2004; 10: 12PO62 [abstract].
• 77 Krause M, Königs C, Kessel C. et al. Epitope mapping of inhibitory antibodies and inhibitor elimination with rituximab in patients with acquired haemophilia. J Thromb Haemost 2005; 03 (Suppl. 01) P0201 [abstract].
• 78 Abdallah A, Coghlan DW, Duncan EM. et al. Rituximab-induced long-term remission in patients with refractory acquired hemophilia. J Thromb Haemost 2005; 03: 2589-90.
• 79 Aggarwal A, Grewal R, Green RJ. et al. Rituximab for autoimmune haemophilia:a proposed treatment algorithm. Haemophilia 2005; 11: 13-9.
• 80 Holme PA, Brosstad F, Tjonnfjord GE. Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies. Haemophilia 2005; 11: 510-15.
• 81 Maruscak M, Cohan B, Aghakhanian L. et al. Rituximab in the treatment of factor VIII inhibitor. Blood 2005; 106: 4064 [abstract].
• 82 Field JJ, Fenske TS, Blinder MA. Rituximab for the treatment of high titer acquired factor VIII inhibitors refractory to conventional chemotherapy. Blood 2005; 106: 3212 [abstract].
• 83 Hut-Kuhne A, Lages P, Zimmermann R. Successful inhibitor elimination with rituximab in acquired hemophilia A and a patient with a carrier status for hemophilia A – two case reports. J Thromb Haemost 2005; 03 (Suppl. 01) P1830 [abstract].
• 84 Wight J, Paisley S, Knight C. Immune tolerance induction in patients with haemophilia A with inhibitors: a systematic review. Haemophilia 2003; 09: 436-63.
• 85 Linde R, Ettinghausen CE, Voigt B. et al. First successful elimination with a new protocol in a high responding hemophilia A patient after failure of various immune tolerance induction regimens. Blood 2001; 98: 2236a [abstract].
• 86 Linde R, Ettinghausen CE, Konigs C. et al. Rituximab as a new inhibitor elimination agent in high titer inhibitor patients – a long term follow-up. Haemophilia 2004; 10: 12PO51 [abstract].
• 87 Medeiros BC, Geraghty S, Stabler SP. Improved response to immune tolerance therapy for factor VIII inhibitor after rituximab therapy. Blood 2002; 100: 3890b [abstract].
• 88 Escobar M, Kempton C, Ma A. Successful treatment of an autoantibody in congenital hemophilia with rituximab. Blood 2002; 100: 3915b [abstract].
• 89 Curtin J, Misra A, Teo J. et al. Use of rituximab as an alternative strategy for the management of difficult high titre inhibitors in children with hemophilia. Haemophilia 2004; 10: 12PO30 [abstract].
• 90 Pruthi RK, Schmidt KA, Slaby JA. et al. Rituximab treatment of FVIII inhibitors in congenital hemophilia A. J Thromb Haemost 2005; 03 (Suppl. 01) P0652 [abstract].
• 91 Dunkley S, Lindeman R. Successful treatment of a high titer factor VIII inhibitor with rituximab alone. J Thromb Haemost 2005; 03 (Suppl. 01) P0631 [abstract].
• 92 Carcao M, St Louis J, Poon MC. et al. on behalf of the Inhibitor Subcommittee of the Association of Hemophilia Clinic Directors of Canada. Rituximab for congenital hemophiliacs with inhibitors: a Canadian experience. Haemophilia 2006; 12: 7-18.
• 93 Moschovi M, Aronis S, Trimis G. et al. Rituximab in the treatment of high responding inhibitors in severe hemophilia A. Haemophilia 2006; 12: 95-9.
• 94 Lian EC, Tzakis AG, Andrews D. Response of factor V inhibitor to rituximab in a patient who received liver transplantation for primary biliary cirrhosis. Am J Hematol 2004; 77: 363-5.
• 95 Miesbach W. Rituximab in the treatment of factor XIII inhibitor possibly caused by ciprofloxacin. Thromb Haemost 2005; 93: 1001-3.